Compare Novo Nordisk A/S (NVO) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Trip.com Group Ltd — how do they compare? Novo Nordisk A/S trades at $49.31 (market cap $220.53B), while Trip.com Group Ltd trades at $43.78 (market cap $28.12B). The key difference: Novo Nordisk A/S is far larger — about 7.8× Trip.com Group Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | TCOM | |
|---|---|---|
Market Cap | $220.53B | $28.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $78.96 |
52-Week Low | $35.29 | $39.84 |
Enterprise Value | $239.49B | $20.82B |
Dividend Yield | 3.63% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Trip.com Group (TCOM) trades at $43.65, up 2.83% with strong fundamentals including a 6.64 P/E ratio and 48.65% net margin. Recent Q1 2026 earnings missed expectations at $0.83 per share versus $0.85 expected, though revenue grew 17% year-over-year. Technical indicators show a bullish overall signal with resistance near $45, while news highlights institutional buying and regulatory scrutiny concerns.
The outlook remains positive with a $56.72 analyst price target implying 30% upside, supported by robust cash flow and expanding profitability. Key risks include Q2 revenue guidance of 3%-8% growth lagging expectations and ongoing antitrust investigations in China that could pressure margins near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
